AR014406A1 - SULFONYL PHENYLAMINES REPLACED AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM - Google Patents
SULFONYL PHENYLAMINES REPLACED AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEMInfo
- Publication number
- AR014406A1 AR014406A1 ARP980106523A ARP980106523A AR014406A1 AR 014406 A1 AR014406 A1 AR 014406A1 AR P980106523 A ARP980106523 A AR P980106523A AR P980106523 A ARP980106523 A AR P980106523A AR 014406 A1 AR014406 A1 AR 014406A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- substituted
- carbamoyl
- amino
- Prior art date
Links
- -1 SULFONYL PHENYLAMINES Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- QLRBNEZOQPLERN-UHFFFAOYSA-N (sulfonylamino)benzene Chemical class O=S(=O)=NC1=CC=CC=C1 QLRBNEZOQPLERN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000005237 alkyleneamino group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Sulfonilfenilaminas sustituidas de la formula (I), en donde: X es S o NH, e Y y Z son cada uno CH; o X es NH, y una de las variables Y y Z es N, y la otraes CH; R1 y R2, independientemente uno del otro, presentan hidrogeno, alquilo (C1-7), o alquilo (C1-7) sustituido por hidroxi, halogeno, alcoxi (C1-7),carboxi, alcoxi (C1-7)-carbonilo, carbamoílo, alquilo (C1-7)-carbamoílo, dialquilo (C1-7)-carbamoílo, cicloalquilo (C3-8), o por cicloalquilo (C3-8) queestá sustituido por alcoxi (C1-7)-carbonilo, o representan alcanoílo (C2-7); mientras que cuando menos una de las variables R1 y R2 es diferente dehidrogeno; o el grupo NR1R2 es alquileno (C2-6)-amino lineal que está insustituido o sustituido por alquilo (C1-7), hidroxialquilo (C1-7), alcoxi(C1-7), alcoxi (C1-7)-alquilo (C1-7), alcoxi (C1-7)-alcoxi (C1-7)-alquilo (C1-7), tioalquilo (C1-7)-alquilo (C1-7), alcano (C1-7)-sulfinilalquilo (C1-7),alcano (C1-7)-sulfonilalquilo (C1-7), aminoalquilo (C1-7), alquilo (C1-7)- aminoalquilo (C1-7), dialquilo (C1-7)-aminoalquilo (C1-7), hidroxi, ciano,amino, alquilo (C1-7)-amino, dialquilo (C1-7)-amino, alcanoílo (C1-7), hidroxilimino-alquilo (C2-7), carboxi, alcoxi (C1-7)-carbonilo, carbamoílo,alquilo (C1-7)-carbamoílo, dialquilo (C1-7)-carbamoílo, o por oxo, o es morfolino, tiomorfolino, 4-alquilo (C1-7)-piperazino, 4-piridil-piperazino,tetrahidroquinolin-1-ilo, tetrahidroiso-quinolin-2-ilo, dihidroindol-1-ilo, o dihidroindol-1-ilo sustituido por alcoxi (C1-7)-carbonilo, o es un grupo de laformula (II); y en donde el anillo A, aparte de estar sustituido por -SO2NR1R2 y -NH-, está insustituido o sustituido una o más veces por un sustituyenteseleccionado a partir del grupo que consisteen alquilo (C1-7), alcoxi (C1-7), alcoxi (C1-7)-alcoxi (C1-7), hidroxi, halogeno, y CF3; y en donde el anillo BSubstituted sulfonylphenylamines of the formula (I), wherein: X is S or NH, and Y and Z are each CH; or X is NH, and one of the variables Y and Z is N, and the other is CH; R1 and R2, independently of each other, have hydrogen, (C1-7) alkyl, or (C1-7) alkyl substituted by hydroxy, halogen, (C1-7) alkoxy, carboxy, (C1-7) alkoxycarbonyl, carbamoyl, (C1-7) alkyl -carbamoyl, dialkyl (C1-7) -carbamoyl, cycloalkyl (C3-8), or by cycloalkyl (C3-8) which is substituted by (C1-7) alkoxycarbonyl, or represent alkanoyl (C2-7); while at least one of the variables R1 and R2 is different from hydrogen; or the NR1R2 group is linear (C2-6) alkyleneamino which is unsubstituted or substituted by (C1-7) alkyl, hydroxy (C1-7) alkyl, (C1-7) alkoxy, (C1-7) alkoxy ( C1-7), (C1-7) alkoxy-(C1-7) alkoxy-(C1-7) alkyl, thioalkyl (C1-7) -alkyl (C1-7), alkane (C1-7) -sulfinylalkyl (C1 -7), (C1-7) alkane-sulfonyl (C1-7) alkyl, amino (C1-7) alkyl, (C1-7) alkyl-amino (C1-7), dialkyl (C1-7) -aminoalkyl (C1- 7), hydroxy, cyano, amino, (C1-7) -amino, dialkyl (C1-7) -amino, (C1-7) alkanoyl, hydroxyimino-(C2-7) alkyl, carboxy, (C1-7) alkoxy ) -carbonyl, carbamoyl, (C1-7) alkyl -carbamoyl, dialkyl (C1-7) -carbamoyl, or by oxo, or is morpholino, thiomorpholino, 4-alkyl (C1-7) -piperazino, 4-pyridyl-piperazino , tetrahydroquinolin-1-yl, tetrahydroiso-quinolin-2-yl, dihydroindole-1-yl, or dihydroindole-1-yl substituted by (C1-7) alkoxycarbonyl, or is a group of laformula (II); and wherein ring A, apart from being substituted by -SO2NR1R2 and -NH-, is unsubstituted or substituted one or more times by a substituent selected from the group consisting of (C1-7) alkyl, (C1-7) alkoxy, (C1-7) alkoxy (C1-7) alkoxy, hydroxy, halogen, and CF3; and where ring B
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19757248 | 1997-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014406A1 true AR014406A1 (en) | 2001-02-28 |
Family
ID=7853006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106523A AR014406A1 (en) | 1997-12-22 | 1998-12-18 | SULFONYL PHENYLAMINES REPLACED AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR014406A1 (en) |
| AU (1) | AU2415299A (en) |
| CO (1) | CO5011105A1 (en) |
| PE (1) | PE20000127A1 (en) |
| WO (1) | WO1999032466A1 (en) |
| ZA (1) | ZA9811705B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2350714A1 (en) | 1998-11-10 | 2000-05-18 | Merck & Co., Inc. | Spiro-indolines as y5 receptor antagonists |
| FR2792314B1 (en) * | 1999-04-15 | 2001-06-01 | Adir | NOVEL AMINOTRIAZOLE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US6218408B1 (en) | 1999-06-30 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (bicyclics) |
| US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
| US6989379B1 (en) | 1999-04-22 | 2006-01-24 | H. Lundbick A/S | Selective NPY (Y5) antagonists |
| EP1183245B1 (en) * | 1999-04-22 | 2007-05-09 | H. Lundbeck A/S | Selective npy (y5) antagonists |
| US6225330B1 (en) | 1999-06-30 | 2001-05-01 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (tricyclics) |
| US6214853B1 (en) | 1999-06-30 | 2001-04-10 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (bicyclics) |
| US6222040B1 (en) | 1999-06-30 | 2001-04-24 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (tricyclics) |
| US7273880B2 (en) | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
| DK1249233T3 (en) * | 1999-11-26 | 2008-11-17 | Shionogi & Co | NPYY5 receptor antagonists |
| JP2003525291A (en) * | 2000-03-01 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 2,4-disubstituted thiazolyl derivatives |
| FR2815346B1 (en) * | 2000-10-13 | 2004-02-20 | Servier Lab | NOVEL AMINOTRIAZOLONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| WO2002078697A1 (en) * | 2001-03-29 | 2002-10-10 | Smithkline Beecham Corporation | Compounds and methods |
| CA2403307A1 (en) | 2001-10-23 | 2003-04-23 | Neurogen Corporation | Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
| TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| BRPI0409447A (en) * | 2003-04-14 | 2006-04-18 | Inst For Pharm Discovery Inc | substituted phenylalkanoic acids |
| EA200501710A1 (en) | 2003-04-30 | 2006-06-30 | ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи | SUBSTITUTED CARBON ACIDS |
| WO2006042215A1 (en) | 2004-10-08 | 2006-04-20 | Janssen Pharmaceutica, N.V. | 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives |
| GB0526257D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| US9353078B2 (en) * | 2013-10-01 | 2016-05-31 | New York University | Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof |
| EP4077290A1 (en) | 2019-12-20 | 2022-10-26 | Ikena Oncology, Inc. | 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders |
| WO2025017207A1 (en) * | 2023-07-20 | 2025-01-23 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Inhibitors of smndc1 and their therapeutic use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3776765A (en) * | 1972-02-28 | 1973-12-04 | Cities Service Co | Process for protecting a substrate with an n{11 substituted aminoarylsulfonamide intumescent agent |
| FR2701480B1 (en) * | 1993-02-15 | 1995-05-24 | Sanofi Elf | Compounds with a sulfamoyl and amidino group, process for their preparation and pharmaceutical compositions containing them. |
| AU3201095A (en) * | 1994-07-27 | 1996-02-22 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
-
1998
- 1998-12-17 CO CO98075202A patent/CO5011105A1/en unknown
- 1998-12-17 PE PE1998001240A patent/PE20000127A1/en not_active Application Discontinuation
- 1998-12-18 AR ARP980106523A patent/AR014406A1/en unknown
- 1998-12-18 WO PCT/EP1998/008333 patent/WO1999032466A1/en not_active Ceased
- 1998-12-18 AU AU24152/99A patent/AU2415299A/en not_active Abandoned
- 1998-12-21 ZA ZA9811705A patent/ZA9811705B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA9811705B (en) | 1999-09-07 |
| AU2415299A (en) | 1999-07-12 |
| PE20000127A1 (en) | 2000-03-14 |
| CO5011105A1 (en) | 2001-02-28 |
| WO1999032466A1 (en) | 1999-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR014406A1 (en) | SULFONYL PHENYLAMINES REPLACED AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
| BR0312695A (en) | Cis-alkoxy substituted spirocyclic 1h-pyrrolidine-2,4-dione derivatives | |
| DK0639577T3 (en) | Phosphonooxymethyl or methylthiomethyl esters of taxane derivatives as antitumor agents | |
| BR0213924A (en) | Polymerizable composition, photochromic polymerizate and photochromic article | |
| ES2059207T3 (en) | PROCEDURE FOR THE PREPARATION OF DERIVATIVES FROM TAXANE, NEW DERIVATIVES OBTAINED AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| PE20050081A1 (en) | NEW IMIDAZOPYRAZINES AS INHIBITORS OF CYCLINE-DEPENDENT KINASES | |
| BR0307833A (en) | Controlled synthesis of ziprasidone and its compositions | |
| CL2023000394A1 (en) | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsufonamide analogues as cereblon protein modulators | |
| AR011093A1 (en) | COMPOUNDS DERIVED FROM SULFONIL UREA, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND PROCEDURE FOR ITS USE. | |
| CO5540344A2 (en) | MEDICINES | |
| FR2763244B1 (en) | MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER | |
| CR6592A (en) | COMPOUNDS FOR THE TREATMENT OF THE ISCHEMIA | |
| PA8539801A1 (en) | DERIVATIVES OF THE ISOFTALIC ACID AS INHIBITORS OF METALOPROTEINASES OF THE MATRIX | |
| AR015439A1 (en) | DERIVATIVES OF PIRIMIDIN-4-ONA AND PIRIMIDIN-4-TIONA, COMPOSITION TO CONTROL AND PREVENT PESTS, THE USE OF SUCH COMPOUNDS FOR THE PROTECTION OF PLANTS, METHOD FOR CONTROLLING OR PREVENTING THE INFECTION OF PLANTS CULTIVATED BY MICROORGANISMS OF FITOPATODATION METHODS OF PREPARATION SAID DERIVA | |
| DE68927697D1 (en) | Fluorine substituted benzocycloheptapyridines, compositions and methods of using the same as antihistaminic compounds | |
| AR071043A1 (en) | L-GLUTAMIC ACID MARKED WITH (F -18), L- GLUTAMINE MARKED WITH (F-18), ITS DERIVATIVES AND ITS USE, AS WELL AS PROCEDURES FOR THEIR PREPARATION | |
| BR0000654A (en) | Preparation of peroxide vulcanized rubber composition and articles having at least one of its components | |
| DK0811001T3 (en) | Benzothiazine dioxides as endothelin antagonists | |
| AR009145A1 (en) | GUANIDINYL HETERO-CYCLE COMPOUNTS USEFUL AS ALPHA-2 ADRENORECEPTOR AGONISTS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
| BR0210238A (en) | New Aryl-Amino-Propane Analogs and Their Use for the Treatment of Glaucoma | |
| CO4750751A1 (en) | FUNGICIDAL COMPOSITIONS OF TWO COMPONENTS BASED ON METALAXYL TO CONTROL AND PREVENT FUNGAL INFESTATION OF PLANTS AND THEIR ENVIRONMENT | |
| ATE353082T1 (en) | INHIBITORS OF GPIB-VWF INTERACTION | |
| ES2066546T3 (en) | PHARMACEUTICAL COMPOSITION TO INHIBIT THE OSEA RESORPTION. | |
| ES2071036T3 (en) | DERIVATIVES OF 6-O-METHYLERITHROMYCIN TO OXIME. | |
| ES2174669B1 (en) | TRISRESORCINILTRIAZINAS. |